NeuroScientific Biopharmaceuticals is committed to a research and development program that is methodically planned, efficiently executed and risk aware.
The company is developing a Emtin peptides that are modeled on the domains of a naturally occurring protein called Metallothionein-II (MT-II). EmtinB is the lead candidate that has shown to closely mimic the neuroprotective and neuroregenerative ability of MT-II.
EmtinB therapeutic peptide: being developed as treatment for neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve.
The mechanism of action of EmtinB is thought to occur via binding to surface-based cell receptors belonging to the LDLR family, which activate intracellular signaling pathways that “turn on” survival promoting processes of neurons.
EMTINB – MECHANISM OF ACTION